Advances in Brief Amplification of Urokinase Gene in Prostate Cancer 1

Prostate cancer is the most common male malignancy in the United States as well as in many European countries. It is curable as long as it is localized, but the invasion of prostate cancer and formation of metastasis turn it into a life-threatening disease. Urokinase-type plasminogen activator (uPA) is believed to play a key role in tissue degradation and cell migration under various normal and pathological conditions, including cancer invasion and metastasis. Increased expression of uPA has been reported in various malignancies including prostate cancer. However, the mechanisms of the overexpression have remained poorly understood. Here, we report increased copy number ofuPA gene in 3 of 13 hormonerefractory prostate carcinomas, including 1 high-level amplification. Realtime quantitative reverse transcription-PCR showed that the increased expression of uPA coincided with the amplification of the gene in these tumors. Matrigel invasion assay showed that prostate cancer cell line PC-3, containing amplification of theuPA gene, was more sensitive to the urokinase inhibitor, amiloride, than DU145 or LNCaP cell lines, which do not have the amplification. The findings suggest that one of the mechanisms underlying the overexpression of the uPA is the amplification of the gene, which is associated with the increased invasive potential of the cells.

[1]  T. Visakorpi,et al.  Molecular cytogenetics of prostate cancer , 2000, Microscopy research and technique.

[2]  D. Slamon,et al.  Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. , 2000, Seminars in oncology.

[3]  P. Russell,et al.  Urokinase‐type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer‐specific survival and potential therapeutic targets , 2000, International journal of cancer.

[4]  R. Sager,et al.  The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. , 2000, Cancer research.

[5]  C. Larsson,et al.  Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping , 2000, Cytogenetic and Genome Research.

[6]  I. Bièche,et al.  Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. , 1999, Cancer research.

[7]  J. Foekens,et al.  Clinical relevance of the urokinase plasminogen activator system in breast cancer , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[8]  B. Nielsen,et al.  Cancer invasion and tissue remodeling‐cooperation of protease systems and cell types , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[9]  H. Miyake,et al.  Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. , 1999, International journal of oncology.

[10]  T. Visakorpi,et al.  Genetic alterations in hormone-refractory recurrent prostate carcinomas. , 1998, The American journal of pathology.

[11]  T. Visakorpi,et al.  Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. , 1998, Cancer genetics and cytogenetics.

[12]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[13]  E. Skrzypczak‐Jankun,et al.  Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. , 1997, Cancer research.

[14]  U J Balis,et al.  The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. , 1997, BioTechniques.

[15]  R. Sadasivan,et al.  Urokinase-type plasminogen activator expression in human prostate carcinomas. , 1996, The American journal of the medical sciences.

[16]  T. Visakorpi,et al.  Genetic basis and clonal evolution of human prostate cancer. , 1996, Advances in cancer research.

[17]  M. Maruyama,et al.  Prostate‐specific antigen activates single‐chain urokinase‐type plasminogen activator , 1995, International journal of cancer.

[18]  E. Hedley‐Whyte,et al.  Prognostic role of urokinase-type plasminogen activator in human gliomas. , 1995, The American journal of pathology.

[19]  M. Webber,et al.  Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[21]  N. Brünner,et al.  The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion , 1995 .

[22]  E. Verrusio,et al.  Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. , 1994, Cancer research.

[23]  T. Visakorpi,et al.  Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. , 1994, Cytometry.

[24]  A. Mazar,et al.  Expression of Urokinase and Its Receptor in Invasive and Non-Invasive Prostate Cancer Cell Lines , 1992, Thrombosis and Haemostasis.

[25]  J. Reynolds,et al.  The Role of Plasmhogen Activators in the Regulation of Connective Tissue Metalloproteinases a , 1992 .

[26]  K. Danø,et al.  Plasminogen Activation by Receptor-Bound Urokinase , 1991, Seminars in thrombosis and hemostasis.

[27]  F. Blasi,et al.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. , 1991, The American journal of pathology.

[28]  S. Stacey,et al.  Plasminogen activator inhibitors: hormonally regulated serpins , 1990, Molecular and Cellular Endocrinology.

[29]  H. Keer,et al.  Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. , 1989, The Journal of urology.

[30]  F. Blasi,et al.  Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors , 1987, The Journal of cell biology.

[31]  C. Kluft,et al.  Plasminogen activator inhibitors. , 1987, Blood.

[32]  P. Verde,et al.  Human urokinase gene is located on the long arm of chromosome 10. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[33]  K. Danø,et al.  immunocytochemical localization of urokinase-type plasminogen activator in lewis lung carcinoma , 1984, The Journal of cell biology.

[34]  L. Liotta,et al.  Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. , 1981, Cancer research.